4-hydroxy-7-methoxy-2-(6-methyl-2-pyridyl)quinoline | 300831-13-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-hydroxy-7-methoxy-2-(6-methyl-2-pyridyl)quinoline
• 英文别名: 4-hydroxy-7-methoxy-2-(6-methyl-pyridin-2-yl)quinoline；7-Methoxy-2-(6-methyl-2-pyridinyl)-4-quinolinol；7-methoxy-2-(6-methylpyridin-2-yl)-1H-quinolin-4-one
• CAS: 300831-13-4
• 化学式: C₁₆H₁₄N₂O₂
• 分子量: 266.299
• InChiKey: HAKRDTPHYSTDQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS<br/>[FR] PEPTIDES MACROCYCLIQUES ACTIFS CONTRE LE VIRUS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM CA LTD

  公开号：WO2000059929A1

  公开（公告）日：2000-10-12

  The present invention covers macrocyclic compounds of formula (I) active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus wherein W is CH or N; R21 is H, halo, C¿1-6? alkyl, cycloalkyl, haloalkyl, C1-6 alkoxy, cycloalkoxy, hydroxy, or N(R?23)¿2, wherein each R23 is independently H, C¿1-6? alkyl or cycloalkoxy; and R?22¿ is H, halo, C¿1-6? alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 thioalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, C2-7 alkoxyalkyl, C3-6 cycloalkyl, C6 or 10 aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur; said cycloalkyl, aryl or Het being substituted with R?24¿, wherein R24 is H, C¿1-6? alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, NO2, N(R?25)¿2, NH-C(O)-R25; or NH-C(O)-NH-R25, wherein each R25 is independently: H, C¿1-6? alkyl or C3-6 cycloalkyl; or R?24¿ is NH-C(O)-OR26 wherein R26 is C¿1-6? alkyl or C3-6 cycloalkyl; R?3¿ is hydroxy, NH¿2?, or a group of formula -NH-R?31¿, wherein R31 is C6 or 10 aryl, heteroaryl, -C(O)-R32, -C(O)-OR32 or -C(O)-NHR32, wherein R32 is: C¿1-6? alkyl or C3-6 cycloalkyl; D is a 5 to 10-atom saturated or unsaturated alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or N-R?41¿, wherein R41 is H, C¿1-6? alkyl, cycloalkyl or -C(O)-R?42¿, wherein R42 is C¿1-6? alkyl, cycloalkyl or C6 or 10 aryl; R?4¿ is H or from one to three substituents at any carbon atom of said chain D, said substituent independently selected from the group consisting of: C¿1-6? alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxy, halo, amino, oxo, thio or C1-6 thioalkyl, and A is an amide of formula -C(O)-NH-R?5¿, wherein R5 is selected from the group consisting of: C¿1-8? alkyl, C3-6 cycloalkyl, C6 or 10 aryl or C7-16 aralkyl; or A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof.

  本发明涵盖了式（I）的大环化合物，该化合物在体外和细胞试验中对丙型肝炎病毒的NS3蛋白酶具有活性，其中W为CH或N; R21为H，卤素，C1-6烷基，环烷基，卤代烷基，C1-6烷氧基，环烷氧基，羟基或N（R23）2，其中每个R23独立地为H，C1-6烷基或环烷氧基; R22为H，卤素，C1-6烷基，C3-6环烷基，C1-6卤代烷基，C1-6硫代烷基，C1-6烷氧基，C3-6环烷氧基，C2-7烷氧基烷基，C3-6环烷基，C6或10芳基或Het，其中Het是含有1至4个从氮，氧和硫选择的杂原子的五元，六元或七元饱和或不饱和杂环; 所述的环烷基，芳基或Het被R24取代，其中R24为H，C1-6烷基，C3-6环烷基，C1-6烷氧基，C3-6环烷氧基，NO2，N（R25）2，NH-C（O）-R25; 或NH-C（O）-NH-R25，其中每个R25独立地为：H，C1-6烷基或C3-6环烷基; 或R24为NH-C（O）-OR26，其中R26为C1-6烷基或C3-6环烷基; R3为羟基，NH2或式-NH-R31的基团，其中R31为C6或10芳基，杂芳基，-C（O）-R32，-C（O）-OR32或-C（O）-NHR32，其中R32为：C1-6烷基或C3-6环烷基; D为5至10个原子的饱和或不饱和烷基链，可选地包含从O，S或N-R41中独立选择的1至3个杂原子，其中R41为H，C1-6烷基，环烷基或-C（O）-R42，其中R42为C1-6烷基，环烷基或C6或10芳基; R4为H或在链D的任何碳原子上的1至3个取代基，所述取代基独立地选择自以下群：C1-6烷基，C1-6卤代烷基，C1-6烷氧基，羟基，卤素，氨基，氧代，硫代或C1-6硫代烷基; A为式-C（O）-NH-R5的酰胺，其中R5选择自以下群：C1-8烷基，C3-6环烷基，C6或10芳基或C7-16芳基烷基; 或A为羧酸或其药学上可接受的盐或酯。
• Macrocyclic peptides active against the hepatitis C virus
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20040002448A1

  公开（公告）日：2004-01-01

  The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. 1 wherein W, R 21 , R 22 , R 3 , R 4 , D and A are as defined herein, or a pharmaceutically acceptable salt or ester thereof.

  本发明涵盖了公式I的大环化合物，该化合物在体外和细胞测定中对丙型肝炎病毒的NS3蛋白酶具有活性。 其中，W，R21，R22，R3，R4，D和A如此处所定义，或其药学上可接受的盐或酯。
• Macrocyclic peptides inhibiting the hepatitis C virus ns3 protease
  申请人：BOEHRINGER INGELHEIM (CANADA) LTD.

  公开号：EP1437362A1

  公开（公告）日：2004-07-14

  The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. wherein W is CH or N; R21 is H, halo, C1-6 alkyl, cycloalkyl, haloalkyl, C1-6 alkoxy, cycloalkoxy, hydroxy, or N(R23)2, wherein each R23 is independently H, C1-6 alkyl or cycloalkoxy; and R22 is H, halo, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 thioalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, C2-7 alkoxyalkyl, C3-6 cycloalkyl, C6 or 10 aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur; said cycloalkyl, aryl or Het being substituted with R24, wherein R24 is H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkoxy, C3-6 cycloalkoxy, NO2, N(R25)2, NH-C(O)-R25; or NH-C(O)-NH-R25, wherein each R25 is independently: H, C1-6 alkyl or C3-6 cycloalkyl; or R24 is NH-C(O)-OR26 wherein R26 is C1-6 alkyl or C3-6 cycloalkyl; R3 is hydroxy, NH2, or a group of formula - NH-R31, wherein R31 is C6 or 10 aryl, heteroaryl, -C(O)-R32, -C(O)-OR32 or -C(O)-NHR32, wherein R32 is: C1-6 alkyl or C3-6 cycloalkyl; D is a 5 to 10-atom saturated or unsaturated alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or N-R41, wherein R41 is H, C1-6 alkyl, cycloalkyl or -C(O)-R42, wherein R42 is C1-6 alkyl, cycloalkyl or C6 or 10 aryl; R4 is H or from one to three substituents at any carbon atom of said chain D, said substituent independently selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, hydroxy, halo, amino, oxo, thio or C1-6 thioalkyl, and A is an amide of formula -C(O)-NH-R5, wherein R5 is selected from the group consisting of: C1-8 alkyl, C3-6 cycloalkyl, C6 or 10 aryl or C7-16 aralkyl; or A is a carboxylic acid or a pharmaceutically acceptable salt or ester thereof.

  本发明包括在体外和细胞检测中对丙型肝炎病毒 NS3 蛋白酶具有活性的式 I 大环化合物。 其中 W 是 CH 或 N；R21 是 H、卤代、C1-6 烷基、环烷基、卤代烷基、C1-6 烷氧基、环烷氧基、羟基或 N(R23)2，其中每个 R23 独立地是 H、C1-6 烷基或环烷氧基；R22 是 H、卤素、C1-6 烷基、C3-6 环烷基、C1-6 卤代烷基、C1-6 硫代烷基、C1-6 烷氧基、C3-6 环烷氧基、C2-7 烷氧基烷基、C3-6 环烷基、C6 或 10 芳基或 Het，其中 Het 是含有一至四个选自氮、氧和硫的杂原子的五元、六元或七元饱和或不饱和杂环；所述环烷基、芳基或 Het 被 R24 取代，其中 R24 是 H、C1-6 烷基、C3-6 环烷基、C1-6 烷氧基、C3-6 环烷氧基、NO2、N(R25)2、NH-C(O)-R25 或 NH-C(O)-NH-R25，其中每个 R25 独立地是：H、C1-6 烷基或 C3-6 环烷基；或 R24 是 NH-C(O)-OR26，其中 R26 是 C1-6 烷基或 C3-6 环烷基；R3 是羟基、NH2 或式-NH-R31 的基团，其中 R31 是 C6 或 10 芳基、杂芳基、-C(O)-R32、-C(O)-OR32 或-C(O)-NHR32，其中 R32 是：C1-6烷基或C3-6环烷基； D是5至10原子的饱和或不饱和亚烷基链，可任选含有1至3个独立选自以下的杂原子： O、S或N-R41，其中R41是H、C1-6烷基、环烷基或-C(O)-R42，其中R42是C1-6烷基、环烷基或C6或10芳基； R4是H或在所述链D的任一碳原子上的1至3个取代基，所述取代基独立选自以下组成的组：C1-6烷基、C1-6卤代烷基、C1-6烷氧基、羟基、卤代、氨基、氧代、硫代或 C1-6 硫代烷基，以及 A 是式-C(O)-NH-R5 的酰胺，其中 R5 选自由下列组成的组C1-8 烷基、C3-6 环烷基、C6 或 10 芳基或 C7-16 芳烷基；或 A 是羧酸或其药学上可接受的盐或酯。
• MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE
  申请人：BOEHRINGER INGELHEIM (CANADA) LTD.

  公开号：EP1169339A1

  公开（公告）日：2002-01-09
• US6608027B1
  申请人：——

  公开号：US6608027B1

  公开（公告）日：2003-08-19